Trial Profile

A study to investigate INM 750 for the treatment of epidermolysis bullosa simplex

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabinol (Primary)
Indications Epidermolysis bullosa
Focus Adverse reactions; Proof of concept

Most Recent Events

04 Nov 2015 According to an InMed media release, this study is expected to be completed by the end of 2016.
08 Aug 2015 New trial record
06 Aug 2015 InMed anticipates commencing human proof of concept clinical studies of INM-750 in February 2016 with initial data expected by Q3 2016 after which InMed will seek orphan drug designation for INM-750 with the US FDA.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com